P/E at 30.07 vs Industry's 37.25: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd currently trades at a P/E of 30.07, which is approximately 19.3% below the Pharmaceuticals & Biotechnology industry average of 37.25. This discount suggests that the market is pricing in either a relative earnings risk or subdued growth expectations compared to its peers. Given the sector’s elevated valuation, this gap could reflect concerns over the company’s recent performance or broader sector headwinds. The mid-cap stock’s market capitalisation stands at ₹96,843.74 crores, placing it among the larger players in its segment but still below the mega-cap tier.

Performance Across Timeframes: A Mixed Momentum Story

Examining returns over various periods reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has declined by 8.10%, underperforming the Sensex’s 4.73% fall. This underperformance is more pronounced over the last three months, where the stock has lost 8.11% while the Sensex gained 3.24%. Conversely, the one-month return of -0.82% is less severe than the Sensex’s -2.39%, indicating some recent relative resilience. Year-to-date, the stock’s loss of 8.72% is marginally better than the Sensex’s 9.93% decline.

This divergence between short and medium-term returns raises questions about the stock’s near-term catalysts and whether the recent weakness is a continuation of a downtrend or a temporary setback — is this a recovery or a dead-cat bounce? The stock’s one-day performance today was a slight decline of 0.06%, underperforming the sector by 0.38%, and it has been on a two-day losing streak with a cumulative fall of 0.94%.

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd remains weak. The stock is trading below all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This configuration typically signals a sustained downtrend, with no immediate signs of technical recovery. The absence of any short-term moving average crossover above longer-term averages suggests that the stock has yet to establish a base for a potential rebound. The persistent weakness in price relative to these averages aligns with the negative returns observed over the past year and quarter.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

Within the Pharmaceuticals & Biotechnology sector, 34 stocks have declared results recently. Of these, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution indicates a broadly stable sector environment with pockets of strength and weakness. Dr Reddys Laboratories Ltd’s underperformance relative to the sector average and the Sensex suggests company-specific challenges amid a generally mixed sector backdrop.

Rating Reassessment: Previously Rated Hold

The stock was previously rated Hold by MarketsMOJO before its rating was updated on 13 Jul 2026. This reassessment comes amid the valuation discount and the subdued performance metrics. The updated rating reflects a recalibration of the company’s risk-reward profile based on recent data — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The Mojo Score stands at 30.0, consistent with a cautious stance given the prevailing market conditions and technical signals.

Longer-Term Performance: Lagging Broader Market Gains

Over extended periods, Dr Reddys Laboratories Ltd has underperformed the Sensex. The three-year return is 4.00% compared to the Sensex’s 17.39%, while the five-year return is 18.41% versus the Sensex’s 32.04%. Even over a decade, the stock’s 85.78% gain trails the Sensex’s 169.02%. These figures highlight a persistent relative underperformance trend, which may be influencing the current valuation discount and cautious rating stance.

Conclusion: Data Reflects Caution Amid Valuation Discount and Weak Momentum

The data for Dr Reddys Laboratories Ltd paints a picture of a stock trading at a meaningful discount to its sector’s P/E ratio, yet burdened by underperformance across multiple timeframes and a bearish technical setup. The stock’s position below all major moving averages and its negative returns over the past year and quarter contrast with a sector that has delivered mixed but generally stable results. The previous Hold rating has been reassessed in light of these factors — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →